A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE (MVA-BN) Smallpox Vaccine in Healthy, Vaccinia-Naive Subjects
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Modified vaccinia Ankara (Primary)
- Indications Smallpox
- Focus Registrational; Therapeutic Use
- Sponsors Bavarian Nordic
- 20 Feb 2020 According to a Bavarian Nordic media release, in Jan 2020, the company completed the sale of the Priority Review Voucher, granted by the FDA in connection with the approval of JYNNEOS in 2019.
- 24 Sep 2019 According to a Bavarian Nordic media release, concurrent with the approval, FDA granted Bavarian Nordic a Priority Review Voucher (PRV) under the Material Threat Medical Countermeasure PRV program.
- 24 Sep 2019 According to a Bavarian Nordic media release, based on the results of 22 clinical studies including POX-MVA013 and POX-MVA006, U.S. Food and Drug Administration (FDA) has approved JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Non-replicating) (MVA-BN, liquid-frozen) for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.